Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer.
Antiangiogenic therapy is a valuable new approach in the treatment of breast cancer. Response rates ranging from 6.7% to 54% were reported using Bevacizumab (Avastin), anti-vascular endothelial growth factor, with chemotherapy. We report the first case of a patient, with a highly vascular breast cancer that recurred locally while on treatment with paclitaxel and trastuzumab combination, but showed complete clinical and pathological regression upon the addition of bevacizumab therapy to the same combination.